Latest Content

April Armstrong, MD, MPH, discusses choosing AD therapies, JAK inhibitor safety, response measures, and emerging treatments shaping the field.

This study of 26,805 cardiologists shows that industry payments (averaging $3958) are linked to increased Medicare costs, with each $10,000 in payment associated with $14.1 higher beneficiary spending.

Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.

Domain Adaptation leverages lymphoma EHRs to better predict infection risk from treatment-related immune suppression in CLL, boosting Matthews correlation coefficient.

The FDA approved kinase inhibitors, biologics, a pancreatic cancer device, GLP-1 updates, and a new ultrarare disease pathway in February 2026.

New data tracks young-onset colorectal cancer, Medicaid health gaps, pediatric diabetes spikes, and drug-pricing shifts reshaping US care in 2026 highlight this weekly roundup.

Quality evidence is needed to support a new Medicare Part D medication therapy management (MTM) program performance measure, prompting a scoping review on MTM services and associated outcomes.

The politicization of public health is eroding vaccine confidence, risking lower uptake and potential disease outbreaks, says Noel T. Brewer, PhD.

Racial disparities in food insecurity persisted despite income level in US households between 2000 and 2023.